Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIGMENT: PDE6A Gene Therapy for Retinitis Pigmentosa
NCT04611503Phase 2Active, not recruiting
- Sponsor
- STZ eyetrial
- Start
- Sep 2019
- Primary completion
- Jul 2027
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rAAV.hPDE6A in retinitis pigmentosa (RP), sponsored by STZ eyetrial. Primary endpoints: Slit lamp examination at 5 years, Fundus biomicroscopy at 5 years and 1 more. Started Sep 2019; status: active, not recruiting.
02
Drugs
rAAV.hPDE6A
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT04611503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611503.